研发管线
聚焦已验证的的免疫学靶点
立足已验证的免疫学靶点，开发口服小分子药物。
AREA
免疫与炎症
免疫与炎症
免疫与炎症
AREA
实体瘤
实体瘤
在研项目
STAT6抑制剂：针对特应性皮炎、哮喘及其他适应症
IL-4 与 IL-13 是驱动 2 型炎症的关键细胞因子。该炎症由 Th2、ILC2及嗜酸性粒细胞介导，其过度激活可诱发一系列过敏与炎性疾病。通过 Dupilumab 等抗体阻断 IL-4/IL-13 通路，已被证实可有效治疗2 型炎症相关的哮喘、特应性皮炎、过敏性鼻炎及鼻息肉等疾病。
STAT6作为IL-4 与 IL-13 信号通路的关键节点，是驱动 Th2细胞分化、B细胞活化、IgE抗体生成、嗜酸性粒细胞激活及组织炎症的重要转录因子。抑制 STAT6 可阻断2 型炎症过度活化，在多种2型炎症疾病中具备媲美 Dupilumab 疗效的潜力。 我们的 STAT6 小分子抑制剂是一种高效、高选择性的口服药物，兼具生物制剂的疗效与口服小分子疗法的便捷性，有望惠及全球数百万患者。
TNFα: in development for rheumatoid arthritis (RA) and other indications
TNFα is implicated in multiple diseases and is a validated target in autoimmune conditions such as RA. While current biologics are effective, they have limitations. Oral TNFa small molecule inhibitors offer significant advantages over biologics, including ease of administration and reduced immunogenicity.
Our lead candidate is an oral small molecule TNFα inhibitor in development for the treatment of RA, with the potential for broader autoimmune applications. Our candidate has demonstrated a best-in-class small molecule profile and was well-tolerated in preclinical studies.
白介素 17（IL-17）AA + AF抑制剂：针对银屑病、银屑病关节炎及其他多项适应症
IL-17 是银屑病炎症级联反应的关键介质。针对IL-17这一已验证靶点，已有多款大分子上市药物。现有 IL-17大分子抗体抑制剂疗效明确，但存在抗药抗体、渗透性差、成本高、依从性低等局限。
通过双重靶向IL-17 AA 及 AF 异构体，我们的口服小分子抑制剂打破现有疗法的局限，为银屑病及其他多种自身免疫性疾病，带来兼具强效与便捷的治疗新选择。
我们的先导化合物活性显著优于竞品小分子，在临床前动物模型中有效抑制炎症。
STAT6: in discovery for asthma and other indications
STAT6 is a key modulator in type 2 inflammation diseases such as asthma and atopic dermatitis. Injectable anti-IL-4/IL-13 antibodies have demonstrated clinical benefits by suppressing STAT6 activation in multiple type 2 inflammation diseases. However, biologics have limited patient coverage due to the route of administration. Oral STAT6 inhibitors should provide unique advantages with ease of administration and biologic-like activity.
Our lead STAT6 small molecule inhibitors exhibited high potency and selectivity in both biochemical and cellular assays. Future activities are focused on the optimization of pharmacokinetic properties leading to an oral small molecule candidate for clinical development.
